Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Br J Pharmacol ; 169(3): 659-70, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23472879

RESUMEN

BACKGROUND AND PURPOSE: Nitrite (NO2⁻) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2⁻ in healthy volunteers and patients with stable congestive heart failure (CHF). EXPERIMENTAL APPROACH: The acute haemodynamic effects of brachial artery infusion of NO2⁻ (0.31 to 7.8 µmol·min⁻¹) was assessed in normal subjects (n = 20) and CHF patients (n = 21). KEY RESULTS: NO2⁻ infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2⁻ infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (ANOVA: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2⁻ infusion. Venous plasma NO2⁻ concentrations were lower in CHF patients at baseline, and rose substantially less with NO2⁻ infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein-bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2⁻ infusion. Prolonged NO2⁻ exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. CONCLUSIONS AND IMPLICATIONS: The findings of arterial hyper-responsiveness to infused NO2⁻ in CHF patients, with evidence of accelerated transvascular NO2⁻ clearance (presumably with concomitant NO release) suggests that NO2⁻ effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2⁻ as a therapeutic modality in CHF.


Asunto(s)
Insuficiencia Cardíaca/fisiopatología , Nitrito de Sodio/farmacocinética , Vasodilatadores/farmacocinética , Sistema Vasomotor/efectos de los fármacos , Anciano , Arteria Braquial , Estudios de Cohortes , Tolerancia a Medicamentos , Femenino , Antebrazo , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/metabolismo , Hemodinámica/efectos de los fármacos , Humanos , Técnicas In Vitro , Infusiones Intraarteriales , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Óxido Nítrico/administración & dosificación , Óxido Nítrico/análogos & derivados , Óxido Nítrico/metabolismo , Óxido Nítrico/farmacocinética , Nitroglicerina/administración & dosificación , Nitroglicerina/metabolismo , Nitroglicerina/farmacocinética , Nitroglicerina/farmacología , Estrés Oxidativo/efectos de los fármacos , Flujo Sanguíneo Regional/efectos de los fármacos , Vena Safena/efectos de los fármacos , Vena Safena/fisiopatología , Nitrito de Sodio/administración & dosificación , Nitrito de Sodio/metabolismo , Nitrito de Sodio/farmacología , Vasodilatación/efectos de los fármacos , Vasodilatadores/administración & dosificación , Vasodilatadores/metabolismo , Vasodilatadores/farmacología , Sistema Vasomotor/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA